Research Holdings: RCM Leaders Prioritize Automation and Patient Experience in 2026 Strategy
- 76% of revenue cycle management leaders prioritize automation solutions to enhance patient experience by 2026.
- 56% of RCM leaders view automation and AI as key investment areas to streamline processes and improve financial outcomes.
- FinThrive's report advocates integrating patient-centric approaches within RCM to boost both patient satisfaction and operational efficiency.
Transforming Revenue Cycle Management through Automation and Patient Experience
In a significant shift towards prioritizing patient care, FinThrive, Inc. unveils its third annual Transformative Trends and Data-Driven Insights Report, revealing that 76% of revenue cycle management (RCM) leaders are now focusing on automation solutions as their primary initiative for 2026. This emphasis on automation reflects a broader industry trend where enhancing the patient experience has emerged as the foremost organizational goal for 71% of respondents. This marks a pivotal change, as patient experience has outpaced traditional objectives such as cost reduction and revenue enhancement, indicating a shift in the healthcare landscape that prioritizes patient satisfaction alongside financial efficiency.
The report highlights that 56% of RCM leaders view automation and AI as their most significant investment areas. By leveraging these technologies, healthcare organizations aim to streamline revenue cycle processes, improve financial communications, expedite resolutions, and enhance collections while simultaneously reducing operational costs. Hemant Goel, President and CEO of FinThrive, articulates this transformative approach, stating that organizations are transitioning from short-term strategies focused on aggressive cost-cutting to a more holistic view that emphasizes stability, growth, and the role of technology in enhancing patient satisfaction. This shift underscores the interconnectedness of patient experience and revenue growth, where better experiences can lead to increased patient volumes and improved payer mixes.
As the healthcare industry evolves, the findings from FinThrive suggest a significant transformation in how RCM leaders invest strategically in technology. The report advocates for a comprehensive integration of patient-centric approaches within revenue cycle management, illustrating how improved patient experiences can positively impact financial outcomes. Organizations that can successfully merge these objectives are positioned to thrive in an increasingly competitive healthcare environment, reinforcing the importance of innovation in driving both patient satisfaction and operational excellence.
In addition to these insights, the report emphasizes a broader trend in the healthcare industry towards adopting advanced technologies to meet the complexities of modern healthcare delivery. As organizations face rising patient expectations and regulatory demands, the integration of automation and AI becomes crucial in navigating the evolving landscape. The focus on patient experience not only enhances care delivery but also creates a more efficient operational framework that can better adapt to future challenges.
Overall, FinThrive's report signals a critical juncture for RCM leaders as they align their strategies to prioritize patient outcomes while maintaining financial viability. This dual focus may well define the future of healthcare revenue management, marking a transition towards a more patient-centric and technologically advanced system.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…